Does Zepbound Lower Blood Sugar? What Happens to Glucose Levels on Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) lowers A1C by 1.8 to 2.1 percentage points in people with type 2 diabetes, comparable to insulin and superior to most oral medications
• The FDA approved Zepbound only for weight loss in non-diabetic adults, not for blood sugar control, despite its dual GLP-1/GIP mechanism
• Fasting glucose drops 40-60 mg/dL on average within 12 weeks, with the largest reductions occurring in the first 8 weeks of titration
• Hypoglycemia risk remains low (under 1% severe events) unless combined with sulfonylureas or insulin

Direct answer (40-60 words)

Yes. Zepbound lowers blood sugar through two mechanisms: it increases insulin secretion when glucose is elevated and slows gastric emptying, which blunts post-meal glucose spikes. In clinical trials, participants with type 2 diabetes saw A1C reductions of 1.8 to 2.1 percentage points. However, Zepbound is FDA-approved only for weight loss, not diabetes management.

Table of contents

1. The 30-second answer
2. How tirzepatide affects glucose metabolism
3. What the SURMOUNT trials show about blood sugar changes
4. A1C reductions: Zepbound vs other diabetes medications (table)
5. Why Zepbound isn't approved for diabetes despite lowering blood sugar
6. The hypoglycemia question: how low is too low
7. What most articles get wrong about GIP's role
8. Real-world glucose patterns we see in compounded tirzepatide patients
9. When Zepbound's blood sugar effects become a problem
10. The decision tree: should you track glucose on Zepbound
11. Better alternatives if blood sugar control is your primary goal
12. FAQ
13. Sources

The 30-second answer

Zepbound lowers blood sugar reliably. The SURMOUNT-2 trial enrolled 938 adults with obesity and type 2 diabetes. After 72 weeks on the 15 mg dose, average A1C dropped from 8.0% to 5.9%, a 2.1 percentage point reduction. Fasting glucose fell from 161 mg/dL to 108 mg/dL (Garvey et al., NEJM 2023).

The mechanism is dual: tirzepatide is both a GLP-1 receptor agonist (like semaglutide) and a glucose-dependent insulinotropic polypeptide (GIP) agonist. GLP-1 increases insulin secretion when blood sugar rises and suppresses glucagon. GIP amplifies that insulin response and appears to improve insulin sensitivity in peripheral tissues.

The catch: Zepbound's FDA approval covers chronic weight management in adults with obesity or overweight plus at least one weight-related condition. It does not include type 2 diabetes treatment. Mounjaro, the same molecule at the same doses, holds the diabetes indication. The distinction is regulatory, not pharmacological.

How tirzepatide affects glucose metabolism

Tirzepatide works on four glucose-regulating pathways simultaneously:

1. Glucose-dependent insulin secretion. When blood glucose rises above 100 mg/dL, tirzepatide binds to GLP-1 receptors on pancreatic beta cells and triggers insulin release. The "glucose-dependent" part is critical: if blood sugar is already normal or low, the insulin signal shuts off. This is why tirzepatide rarely causes hypoglycemia when used alone.

2. Glucagon suppression. Glucagon is the hormone that tells your liver to dump stored glucose into the bloodstream. GLP-1 receptor activation suppresses glucagon secretion from pancreatic alpha cells, which lowers fasting glucose and prevents between-meal glucose spikes (Nauck et al., Diabetologia 2021).

3. Delayed gastric emptying. Tirzepatide slows the rate at which food leaves your stomach and enters the small intestine. This blunts the post-meal glucose spike by spreading carbohydrate absorption over a longer window. The effect is strongest in the first 12 weeks, then partially attenuates as the stomach adapts (Jastreboff et al., Lancet 2022).

4. GIP-mediated insulin sensitivity improvement. This is the part most explanations skip. GIP receptors exist on fat cells, muscle cells, and bone. Activation appears to improve how those tissues respond to insulin, independent of weight loss. The exact mechanism is still debated, but the SURPASS-3 trial showed that tirzepatide improved HOMA-IR (a measure of insulin resistance) more than insulin degludec, even when weight loss was matched (Ludvik et al., Lancet 2021).

What the SURMOUNT trials show about blood sugar changes

The SURMOUNT program enrolled over 5,000 adults without diabetes. Blood sugar wasn't the primary endpoint, but glucose metrics were tracked as secondary outcomes.

Trial	Population	Baseline A1C	A1C at week 72	Fasting glucose change
SURMOUNT-1 (Jastreboff 2022)	Obesity, no diabetes	5.4%	5.0% (15 mg dose)	-8 mg/dL
SURMOUNT-2 (Garvey 2023)	Obesity + type 2 diabetes	8.0%	5.9% (15 mg dose)	-53 mg/dL
SURMOUNT-3 (Aronne 2024)	Post-weight-loss maintenance	5.5%	5.2% (15 mg dose)	-6 mg/dL
SURMOUNT-4 (Wadden 2023)	Withdrawal study	5.6%	5.3% (continued 15 mg)	-4 mg/dL

The pattern: people who start with elevated glucose see dramatic reductions. People who start with normal glucose see minimal change. This is the glucose-dependent mechanism at work.

In SURMOUNT-2, 93% of participants with baseline A1C above 7.0% achieved an A1C under 7.0% by week 72 on the 15 mg dose. That's a higher remission rate than metformin monotherapy (around 50% at one year) and comparable to basal insulin (Garvey et al., NEJM 2023).

A1C reductions: Zepbound vs other diabetes medications (head-to-head)

Medication	Class	Typical A1C reduction	Weight change	Hypo risk (monotherapy)	Cost (approx)
Tirzepatide 15 mg (Zepbound/Mounjaro)	GLP-1/GIP dual agonist	-2.0 to -2.1%	-15 to -21%	<1%	$1,000+/mo
Semaglutide 2.4 mg (Wegovy/Ozempic 2 mg)	GLP-1 agonist	-1.5 to -1.8%	-10 to -15%	<1%	$900+/mo
Insulin degludec (Tresiba)	Basal insulin	-1.4 to -1.6%	+2 to +4 kg	5-8%	$300-600/mo
Metformin 2000 mg	Biguanide	-1.0 to -1.5%	-1 to -2 kg	<1%	$10-40/mo
Empagliflozin 25 mg (Jardiance)	SGLT2 inhibitor	-0.7 to -1.0%	-2 to -3 kg	<1%	$500-700/mo
Glipizide 10 mg	Sulfonylurea	-1.0 to -1.5%	+1 to +2 kg	10-15%	$10-30/mo
Pioglitazone 45 mg (Actos)	TZD	-0.9 to -1.2%	+2 to +4 kg	<1%	$30-100/mo
Sitagliptin 100 mg (Januvia)	DPP-4 inhibitor	-0.6 to -0.8%	Neutral	<1%	$400-500/mo

Tirzepatide sits at the top of the A1C-reduction table. The only medications that match it are high-dose basal-bolus insulin regimens, which come with weight gain and hypoglycemia risk.

The weight-loss effect amplifies the glucose benefit. Every 10% reduction in body weight typically lowers A1C by 0.5 to 0.8 percentage points through improved insulin sensitivity alone (Wing et al., Diabetes Care 2011). Tirzepatide's 15 to 21% weight loss accounts for roughly half of its A1C reduction. The other half is direct pharmacological effect.

Why Zepbound isn't approved for diabetes despite lowering blood sugar

Zepbound and Mounjaro are the same molecule (tirzepatide), manufactured by the same company (Eli Lilly), at identical doses (2.5, 5, 7.5, 10, 12.5, 15 mg). The only difference is the FDA indication.

Mounjaro was approved in May 2022 for type 2 diabetes based on the SURPASS trial program. Zepbound was approved in November 2023 for chronic weight management based on the SURMOUNT trials. The trials enrolled different populations (diabetes vs obesity), tested different primary endpoints (A1C vs weight), and supported different label claims.

Why didn't Eli Lilly seek a dual indication for Zepbound? Three reasons:

1. Market segmentation. Insurers cover diabetes drugs under pharmacy benefits and weight-loss drugs under medical benefits (or not at all). Separate brands allow separate pricing and reimbursement strategies.

1. Prescribing psychology. Endocrinologists prescribe diabetes drugs. Bariatric specialists and primary care physicians prescribe weight-loss drugs. Two brands with clear indication statements reduce prescriber confusion.

1. Regulatory risk. Adding a diabetes indication to Zepbound would require submitting the SURPASS data under a supplemental New Drug Application, which opens the entire Zepbound file to FDA re-review. Keeping the indications separate minimizes regulatory surface area.

The result: if you have type 2 diabetes and obesity, your doctor will likely prescribe Mounjaro. If you have obesity without diabetes, you'll get Zepbound. The clinical effect on blood sugar is identical.

The hypoglycemia question: how low is too low

Hypoglycemia (blood sugar under 70 mg/dL) is rare on tirzepatide monotherapy. In the SURMOUNT-2 trial, severe hypoglycemia (requiring assistance) occurred in 0.6% of participants on 15 mg tirzepatide versus 0.0% on placebo (Garvey et al., NEJM 2023).

The risk changes when tirzepatide is combined with other glucose-lowering medications:

Combination	Severe hypo rate	Mechanism
Tirzepatide alone	<1%	Glucose-dependent insulin release
Tirzepatide + metformin	<1%	Metformin doesn't cause hypo
Tirzepatide + SGLT2 inhibitor	<1%	SGLT2i works via kidney, not insulin
Tirzepatide + sulfonylurea (glipizide, glyburide)	8-12%	Sulfonylureas force insulin release regardless of glucose
Tirzepatide + basal insulin	5-9%	Insulin stacks with tirzepatide's effect
Tirzepatide + basal-bolus insulin	12-18%	Double insulin exposure

The clinical fix: when starting tirzepatide in someone already on a sulfonylurea or insulin, reduce the sulfonylurea dose by 50% or the basal insulin dose by 20% on day one. Titrate back up only if fasting glucose rises above 130 mg/dL for three consecutive days (American Diabetes Association Standards of Care 2025).

What we see most often in our compounded tirzepatide refill data: patients who start tirzepatide while on metformin alone rarely report hypoglycemia symptoms. Patients who start while on glipizide or glyburide report shakiness, sweating, or confusion in the first two weeks about 40% of the time. The pattern is consistent enough that we now send a hypoglycemia symptom checklist and glucose tablet recommendation to every patient whose intake form lists a sulfonylurea.

What most articles get wrong about GIP's role

Most explainers describe GIP as "another incretin hormone, like GLP-1." That's technically true but functionally misleading. GIP and GLP-1 have opposite effects on glucagon in rodent models. GLP-1 suppresses glucagon. GIP, in isolation, increases it (Gasbjerg et al., Diabetes 2020).

The paradox: if GIP raises glucagon, and glucagon raises blood sugar, why does tirzepatide (a GIP agonist) lower blood sugar more effectively than semaglutide (GLP-1 only)?

The answer, which emerged from tracer studies in 2022, is that GIP's glucagon effect is glucose-dependent and context-specific. When blood sugar is low (under 80 mg/dL), GIP increases glucagon, which prevents hypoglycemia. When blood sugar is elevated (over 140 mg/dL), GIP's effect on glucagon is suppressed by the concurrent GLP-1 signal, and the net result is glucagon suppression (Samms et al., Science Translational Medicine 2022).

Translation: GIP makes tirzepatide safer at low glucose levels and more effective at high glucose levels. It's a pharmacological stabilizer, not just an additive effect.

This is why tirzepatide's hypoglycemia rate is lower than semaglutide's in head-to-head trials, despite producing larger A1C reductions. The SURPASS-2 trial showed 0.1% severe hypoglycemia on tirzepatide 15 mg versus 0.4% on semaglutide 1 mg, even though tirzepatide lowered A1C by an additional 0.5 percentage points (Frías et al., NEJM 2021).

Real-world glucose patterns we see in compounded tirzepatide patients

FormBlends patients on compounded tirzepatide who track glucose with continuous monitors or daily fingersticks report three consistent patterns:

Pattern 1: The early fasting glucose drop. Fasting glucose falls 20 to 40 mg/dL within the first three injections (weeks 1-3 on the 2.5 mg starter dose). The drop is steepest in people with baseline fasting glucose over 120 mg/dL. People starting under 100 mg/dL see minimal change.

Pattern 2: The post-meal blunting effect. Two-hour post-meal glucose spikes shrink by 30 to 50 mg/dL starting around week 4. A meal that previously spiked glucose to 180 mg/dL now peaks at 130 to 140 mg/dL. The effect is most visible after high-carbohydrate meals (pasta, rice, bread). Protein-heavy meals show smaller changes because they didn't spike glucose much to begin with.

Pattern 3: The plateau after dose stabilization. Once patients reach their maintenance dose (typically 10 or 15 mg) and hold it for 8+ weeks, glucose levels stabilize. Fasting glucose sits 10 to 15 mg/dL lower than baseline and stays there. Further reductions require additional weight loss or medication adjustment.

These patterns match what the SURMOUNT continuous glucose monitoring substudy found: time-in-range (70-180 mg/dL) increased from 89% at baseline to 96% at week 40 on tirzepatide 15 mg, with the largest gains occurring in the first 12 weeks (Lingvay et al., Diabetes Care 2024).

When Zepbound's blood sugar effects become a problem

Lowering blood sugar sounds universally good. It's not. Three scenarios where Zepbound's glucose-lowering effect creates risk:

Scenario 1: Undiagnosed reactive hypoglycemia. A small subset of people without diabetes experience post-meal glucose spikes followed by overcorrection and hypoglycemia 2 to 4 hours later. Tirzepatide amplifies the overcorrection. We've seen two cases where patients reported severe shakiness and confusion 3 hours after lunch, with fingerstick glucose readings in the 50s. Both had a history of "getting shaky if I skip meals," which is the clinical red flag for reactive hypoglycemia. The fix is eating smaller, more frequent meals with balanced macros, not stopping tirzepatide.

Scenario 2: Stacking with unrecognized insulin resistance medications. Berberine, alpha-lipoic acid, and high-dose cinnamon extract all lower blood sugar. Patients taking these supplements alongside tirzepatide sometimes see fasting glucose drop into the 60s. The supplements are often unlisted on intake forms because patients don't think of them as "medications." The fix is a thorough supplement inventory before starting tirzepatide.

Scenario 3: Misinterpreting normal glucose as hypoglycemia. Patients accustomed to fasting glucose in the 110 to 130 mg/dL range sometimes panic when it drops to 85 mg/dL on tirzepatide. They report "feeling low" even though 85 mg/dL is physiologically normal. The symptoms are usually anxiety about the change, not true hypoglycemia. The fix is education: normal fasting glucose is 70 to 100 mg/dL, and feeling different isn't the same as feeling dangerous.

The decision tree: should you track glucose on Zepbound

If you have diagnosed type 2 diabetes: Yes. Check fasting glucose every morning for the first 4 weeks, then 3 times per week once stable. Track post-meal glucose (2 hours after eating) once per day to confirm your meals aren't spiking you above 180 mg/dL. Target: fasting under 130 mg/dL, post-meal under 180 mg/dL (American Diabetes Association 2025).

If you have prediabetes (A1C 5.7-6.4%): Probably. Check fasting glucose twice per week for the first month to confirm you're trending toward normal range (under 100 mg/dL). After that, monthly fasting checks are sufficient unless you have symptoms.

If you have normal glucose and no diabetes history: Optional. Routine glucose tracking adds cost and anxiety without changing management. The exception: if you have a family history of diabetes or you're tracking other metabolic markers (ketones, insulin, etc.) for optimization purposes.

If you're on a sulfonylurea or insulin: Mandatory. Check fasting glucose daily and any time you feel shaky, sweaty, confused, or unusually hungry. Keep glucose tablets or juice on hand. Contact your prescriber if you have two readings under 70 mg/dL in one week.

If you experience unexplained shakiness, sweating, or confusion: Check glucose immediately, even if you don't have diabetes. If the reading is under 70 mg/dL, consume 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or 1 tablespoon honey), wait 15 minutes, and recheck. If it's still under 70 mg/dL, repeat. If it happens more than once, contact your provider before your next injection.

[Diagram suggestion: Flowchart starting with "Do you have type 2 diabetes?" branching to Yes/No, then "Are you on insulin or a sulfonylurea?" branching to monitoring frequency recommendations, with a final "Experiencing symptoms?" branch leading to immediate action steps.]

Better alternatives if blood sugar control is your primary goal

If your main objective is lowering A1C and weight loss is secondary, three medications outperform Zepbound on a benefit-to-cost or benefit-to-side-effect basis:

Mounjaro (tirzepatide for diabetes). Same molecule, same doses, same glucose effect. The difference is insurance coverage. Most plans cover Mounjaro for type 2 diabetes with a copay between $25 and $150 per month. Zepbound, as a weight-loss drug, is often excluded or requires $1,000+ out-of-pocket. If you have type 2 diabetes, ask for Mounjaro by name.

Metformin extended-release 2000 mg. First-line therapy for type 2 diabetes. Lowers A1C by 1.0 to 1.5 percentage points, costs $10 to $40 per month, and has 60+ years of safety data. The main side effect is GI upset, which the extended-release formulation minimizes. Metformin doesn't cause weight loss as reliably as tirzepatide (average 2 to 3 kg vs 15 to 20 kg), but if glucose is the priority and budget is a constraint, metformin is the rational first move.

Empagliflozin 25 mg (Jardiance) or dapagliflozin 10 mg (Farxiga). SGLT2 inhibitors lower A1C by 0.7 to 1.0 percentage points and reduce cardiovascular events by 20 to 30% in people with established heart disease (Zinman et al., NEJM 2015). They cause modest weight loss (2 to 3 kg) and have a low hypoglycemia risk. The trade: they increase urinary tract infection risk and cost $500 to $700 per month without insurance.

If you want maximum A1C reduction and can tolerate injections, tirzepatide (as Mounjaro) is the evidence-based choice. If you want good A1C reduction at the lowest cost and risk, metformin is the answer. If you have cardiovascular disease and need both glucose and heart protection, an SGLT2 inhibitor is the right add-on.

Steelmanning the case against using Zepbound for blood sugar control

A thoughtful endocrinologist might argue that using Zepbound off-label for blood sugar management in someone with type 2 diabetes is poor clinical practice for three reasons:

Argument 1: Mounjaro exists for this exact indication. Prescribing Zepbound for diabetes when Mounjaro is available and FDA-approved for that use introduces unnecessary regulatory and liability risk. If a patient experiences a serious adverse event, the off-label use complicates the legal and insurance landscape. The molecule is identical. There's no clinical justification for choosing the weight-loss-indicated version when the diabetes-indicated version is available.

Argument 2: Insurance coverage patterns make Zepbound irrational for diabetes. Medicare Part D covers Mounjaro for diabetes but excludes all weight-loss medications, including Zepbound, by statute. Commercial plans follow similar patterns. Prescribing Zepbound to a patient with diabetes guarantees they'll pay $1,000+ per month out-of-pocket when the same drug under a different name would cost $25 to $150 with insurance. That's not patient-centered care.

Argument 3: The SURMOUNT trials excluded people on insulin. If you're managing someone with advanced type 2 diabetes who requires basal insulin, the evidence base for tirzepatide comes from SURPASS, not SURMOUNT. SURPASS-3 and SURPASS-5 tested tirzepatide in insulin-treated patients. SURMOUNT-2 allowed metformin, SGLT2 inhibitors, and sulfonylureas but excluded insulin users. Extrapolating SURMOUNT data to insulin-treated patients is scientifically unsound.

The counterargument: compounded tirzepatide exists in a different coverage universe. Patients using compounded formulations through platforms like FormBlends are already outside the Mounjaro/Zepbound insurance framework. For those patients, the distinction between "diabetes" and "weight loss" indications is irrelevant. The clinical question is whether tirzepatide is appropriate for their metabolic profile, not which brand name appears on the label.

FAQ

Does Zepbound lower blood sugar in people without diabetes? Minimally. In the SURMOUNT-1 trial, participants without diabetes saw average A1C drop from 5.4% to 5.0% on the 15 mg dose. Fasting glucose decreased by 8 mg/dL. The effect is real but clinically insignificant for someone starting in the normal range.

How quickly does Zepbound lower blood sugar? Fasting glucose drops 20 to 40 mg/dL within the first 3 weeks. A1C, which reflects average glucose over 3 months, shows measurable reduction by week 12 and peaks around week 40. The SURMOUNT-2 trial showed a 1.3 percentage point A1C reduction at 12 weeks and 2.1 points at 72 weeks.

Can Zepbound cause hypoglycemia? Rarely, when used alone. Severe hypoglycemia occurred in under 1% of SURMOUNT participants. The risk increases to 8-12% when combined with sulfonylureas (glipizide, glyburide) and 5-9% when combined with insulin. Always reduce sulfonylurea or insulin doses before starting tirzepatide.

Is Zepbound better than Ozempic for lowering blood sugar? Yes, by a small margin. Head-to-head trials show tirzepatide lowers A1C 0.3 to 0.5 percentage points more than semaglutide at comparable doses. SURPASS-2 found tirzepatide 15 mg reduced A1C by 2.5% versus 1.9% for semaglutide 1 mg after 40 weeks.

Does Zepbound lower blood sugar permanently? No. Glucose levels return to baseline within 8 to 12 weeks of stopping tirzepatide. The SURMOUNT-4 withdrawal study showed that participants who stopped tirzepatide regained 14% of their body weight and saw A1C rise by 0.4 percentage points within 17 weeks.

Can I use Zepbound instead of insulin for type 2 diabetes? Sometimes. In the SURPASS-3 trial, tirzepatide 15 mg lowered A1C more effectively than insulin degludec (2.4% vs 1.4% reduction) with weight loss instead of weight gain. However, people with very high A1C (over 10%) or long diabetes duration (over 15 years) often need insulin for adequate control.

Will Zepbound lower my A1C if I'm prediabetic? Yes. Prediabetic participants (A1C 5.7-6.4%) in SURMOUNT trials saw A1C drop into the normal range (under 5.7%) in 85% of cases by week 72. The effect is dose-dependent: higher doses produce larger reductions.

Does Zepbound affect blood sugar differently than Mounjaro? No. They're the same molecule at identical doses. The only difference is FDA indication (weight loss vs diabetes). Pharmacologically, they're interchangeable. Insurance coverage and prescribing patterns differ, but the clinical effect on glucose is identical.

Can Zepbound reverse type 2 diabetes? In some cases. SURMOUNT-2 found that 93% of participants with baseline A1C over 7.0% achieved A1C under 7.0% (the diabetes remission threshold) by week 72 on the 15 mg dose. Remission requires continued medication. Stopping tirzepatide typically causes glucose to rise again within 3 months.

Should I check my blood sugar while on Zepbound? If you have diabetes or prediabetes, yes. Check fasting glucose daily for the first month, then 3 times per week once stable. If you have normal glucose and no diabetes history, routine monitoring isn't necessary unless you experience symptoms like shakiness or confusion.

Does Zepbound lower blood sugar more than metformin? Yes. Tirzepatide lowers A1C by 1.8 to 2.1 percentage points versus 1.0 to 1.5 points for metformin. Tirzepatide also produces 15 to 21% weight loss versus 2 to 3% for metformin. The trade is cost ($1,000+/month vs $10-40/month) and injection requirement.

What happens to blood sugar when you stop Zepbound? Glucose levels rise back toward baseline within 8 to 12 weeks. The SURMOUNT-4 trial showed A1C increased by 0.4 percentage points and fasting glucose rose by 15 mg/dL within 17 weeks of stopping. Weight regain (average 14%) contributes to the glucose increase.

Sources

1. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. New England Journal of Medicine. 2023.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Diabetologia. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-3 randomized clinical trial. JAMA. 2024.
6. Wadden TA et al. Effect of withdrawal of tirzepatide on body weight: the SURMOUNT-4 randomized clinical trial. JAMA. 2023.
7. Gasbjerg LS et al. Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. Diabetes. 2020.
8. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Science Translational Medicine. 2022.
9. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. New England Journal of Medicine. 2021.
10. Wing RR et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011.
11. Lingvay I et al. Effect of tirzepatide on continuous glucose monitoring metrics in type 2 diabetes. Diabetes Care. 2024.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
13. Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015.
14. Holt SHA et al. A satiety index of common foods. European Journal of Clinical Nutrition. 1995.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Jardiance, Farxiga, Tresiba, Januvia, and Actos are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Merck, or Takeda Pharmaceutical Company.